@inproceedings{KoenigWolf2016,
  author    = {K{\"o}nig, Johannes Alexander and Wolf, Martin},
  title     = {The pyramid assessment framework for 'competence developing games'},
  series = {Communications in Computer and Information Science},
  volume    = {618},
  booktitle = {Communications in Computer and Information Science},
  editor    = {Stephanidis, C.},
  publisher = {Springer},
  isbn      = {978-331940541-4},
  issn      = {1865-0929},
  doi       = {10.1007/978-3-319-40542-1_37},
  pages     = {232 -- 237},
  year      = {2016},
  language  = {en}
}
@book{Feuerriegel2016,
  author    = {Feuerriegel, Uwe},
  title     = {Verfahrenstechnik mit EXCEL: Verfahrenstechnische Berechnungen effektiv durchf{\"u}hren und professionell dokumentieren},
  publisher = {Springer Fachmedien},
  address   = {Wiesbaden},
  isbn      = {978-3-658-02902-9},
  doi       = {10.1007/978-3-658-02903-6},
  pages     = {XVII, 381 Seiten},
  year      = {2016},
  language  = {de}
}
@article{Lind2016,
  author    = {Lind, Thorsten Patric},
  title     = {Zurechenbarkeit des als Mitglied des Aufsichtsrats einer Aktiengesellschaft erlangten Wissens des Prokuristen einer Bank : BGH, Urteil vom 26.04.2016 - XI ZR 108/15 (OLG M{\"u}nchen)},
  series = {LMK : kommentierte BGH-Rechtsprechung ; in Zsarb. mit der Neuen Juristischen Wochenschrift / Lindenmaier-M{\"o}hring},
  journal   = {LMK : kommentierte BGH-Rechtsprechung ; in Zsarb. mit der Neuen Juristischen Wochenschrift / Lindenmaier-M{\"o}hring},
  publisher = {Beck},
  address   = {M{\"u}nchen},
  issn      = {1611-1095},
  pages     = {380532},
  year      = {2016},
  abstract  = {Mit der vorliegenden, parallel entsprechend in 10 weiteren Verfahren ergangenen Entscheidung behandelte der BGH zum wiederholten Male das Gesch{\"a}ftsmodell der Accessio Wertpapierhandelshaus AG („A AG", fr{\"u}her: Wertpapierhandelshaus Driver \& Bengsch AG). Die klagenden Anleger, zun{\"a}chst nur akquiriert durch ein Tagesgeldkonto mit besonders attraktiven Zinsen, schlossen im Weiteren mit dieser einen Verm{\"o}gensverwaltungsvertrag ab. Zur Abwicklung der Wertpapiergesch{\"a}fte er{\"o}ffneten sie {\"u}ber die A AG zugleich ein Depotkonto bei der beklagten Discount-Brokerin. F{\"u}r dieses erhielt die A AG eine Transaktionsvollmacht. Die Discount-Brokerin schuldete nach den Vertragsdokumenten {\"u}ber die gesetzlichen Aufkl{\"a}rungs- und Erkundigungspflichten bei Auftragsausf{\"u}hrung hinaus keine Anlageberatung („execution-only-business"). Durch nach ihrer Behauptung fehlerhafte Anlageberatung der A AG erlitten die Anleger einen Schaden. In dem Rechtsstreit verlangten sie dessen Ersatz von der Discount-Brokerin, da die A AG zwischenzeitlich insolvent wurde.},
  language  = {de}
}
@article{ChwallekFrohn2016,
  author    = {Chwallek, Constanze and Frohn, Sandra},
  title     = {Den Mitarbeitern den R{\"u}cken st{\"a}rken},
  series = {Personalwirtschaft},
  journal   = {Personalwirtschaft},
  number    = {5},
  publisher = {F.A.Z. Business Media},
  address   = {Frankfurt a.M.},
  issn      = {0341-4698},
  pages     = {46 -- 48},
  year      = {2016},
  abstract  = {Ein Drittel der Mitarbeiter der Saint-Gobain Glass Deutschland GmbH hat drei Jahre lang regelm{\"a}ßig seinen R{\"u}cken trainiert. Mit Erfolg, wie eine abschließende Evaluation in Zusammenarbeit mit der FH Aachen zeigt. Die Fehltage der Trainingsteilnehmer sind enorm zur{\"u}ckgegangen, w{\"a}hrend die untrainierten Kollegen weiterhin unter R{\"u}ckenbeschwerden leiden.},
  language  = {de}
}
@inproceedings{StephanHeuermannPrantner2016,
  author    = {Stephan, Achim and Heuermann, Holger and Prantner, Michael},
  title     = {Cutting human tissue with novel atmospheric-pressure microwave plasma jet},
  series = {46th European Microwave Conference (EuMC)},
  booktitle = {46th European Microwave Conference (EuMC)},
  publisher = {IEEE},
  isbn      = {978-2-87487-043-9},
  doi       = {10.1109/EuMC.2016.7824490},
  pages     = {902 -- 905},
  year      = {2016},
  language  = {en}
}
@article{ZhangHeimbachScheeretal.2016,
  author    = {Zhang, Jin and Heimbach, Tycho and Scheer, Nico and Barve, Avantika and Li, Wenkui and Lin, Wen and He, Handan},
  title     = {Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling},
  series = {Journal of Pharmaceutical Sciences},
  volume    = {Volume 105},
  journal   = {Journal of Pharmaceutical Sciences},
  number    = {Issue 4},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {0022-3549},
  doi       = {doi.org/10.1016/j.xphs.2016.01.021},
  pages     = {1398 -- 1404},
  year      = {2016},
  abstract  = {NVS123 is a poorly water-soluble protease 56 inhibitor in clinical development. Data from in vitro hepatocyte studies suggested that NVS123 is mainly metabolized by CYP3A4. As a consequence of limited solubility, NVS123 therapeutic plasma exposures could not be achieved even with high doses and optimized formulations. One approach to overcome NVS123 developability issues was to increase plasma exposure by coadministrating it with an inhibitor of CYP3A4 such as ritonavir. A clinical boost effect was predicted by using physiologically based pharmacokinetic (PBPK) modeling. However, initial boost predictions lacked sufficient confidence because a key parameter, fraction of drug metabolized by CYP3A4 (ƒₘCYP3A4), could not be estimated with accuracy on account of disconnects between in vitro and in vivo preclinical data. To accurately estimate ƒₘCYP3A4 in human, an in vivo boost effect study was conducted using CYP3A4-humanized mouse model which showed a 33- to 56-fold exposure boost effect. Using a top-down approach, human ƒₘCYP3A4 for NVS123 was estimated to be very high and included in the human PBPK modeling to support subsequent clinical study design. The combined use of the in vivo boost study in CYP3A4-humanized mouse model mice along with PBPK modeling accurately predicted the clinical outcome and identified a significant NVS123 exposure boost (∼42-fold increase) with ritonavir.},
  language  = {en}
}
@inproceedings{RieperGebhardtStucker2016,
  author    = {Rieper, Harald and Gebhardt, Andreas and Stucker, Brent},
  title     = {Process parameters for Selective Laser Melting of AgCu7},
  series = {DDMC, Fraunhofer Direct Digital Manufacturing Conference, 3},
  booktitle = {DDMC, Fraunhofer Direct Digital Manufacturing Conference, 3},
  publisher = {Fraunhofer-Verlag},
  address   = {Stuttgart},
  isbn      = {978-3-8396-1001-5},
  pages     = {171 -- 176},
  year      = {2016},
  language  = {en}
}
@article{DallasSalphatiGomezZepedaetal.2016,
  author    = {Dallas, Shannon and Salphati, Laurent and Gomez-Zepeda, David and Wanek, Thomas and Chen, Liangfu and Chu, Xiaoyan and Kunta, Jeevan and Mezler, Mario and Menet, Marie-Claude and Chasseigneaux, Stephanie and Decl{\`e}ves, Xavier and Langer, Oliver and Pierre, Esaie and DiLoreto, Karen and Hoft, Carolin and Laplanche, Loic and Pang, Jodie and Pereira, Tony and Andonian, Clara and Simic, Damir and Rode, Anja and Yabut, Jocelyn and Zhang, Xiaolin and Scheer, Nico},
  title     = {Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model},
  series = {Molecular Pharmacology},
  volume    = {89},
  journal   = {Molecular Pharmacology},
  number    = {5},
  publisher = {ASPET},
  address   = {Bethesda, Md.},
  issn      = {1521-0111},
  doi       = {10.1124/mol.115.102079},
  pages     = {492 -- 504},
  year      = {2016},
  abstract  = {Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp-/-) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murine Bcrp promoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.},
  language  = {en}
}
@techreport{BhattaraiFrotscherDurongetal.2016,
  author    = {Bhattarai, Aroj and Frotscher, Ralf and Durong, Minh Tu{\´a}n and Staat, Manfred},
  title     = {Schlussbericht zu BINGO. Optimierung des Systems Netzimplantat-Beckenboden zur therapeutischen Gewebeverst{\"a}rkung nach der Integraltheorie.},
  address   = {Aachen},
  pages     = {34},
  year      = {2016},
  language  = {de}
}
@article{ScheerWilson2016,
  author    = {Scheer, Nico and Wilson, Ian D.},
  title     = {A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity},
  series = {Drug Discovery Today},
  volume    = {21},
  journal   = {Drug Discovery Today},
  number    = {2},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {1359-6446},
  doi       = {10.1016/j.drudis.2015.09.002},
  pages     = {250 -- 263},
  year      = {2016},
  abstract  = {Mice that have been genetically humanized for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging and promising in vivo models for an improved prediction of the pharmacokinetic, drug-drug interaction and safety characteristics of compounds in humans. The specific advantages and disadvantages of these models should be carefully considered when using them for studies in drug discovery and development. Here, an overview on the corresponding genetically humanized and chimeric liver humanized mouse models described to date is provided and illustrated with examples of their utility in drug metabolism and toxicity studies. We compare the strength and weaknesses of the two different approaches, give guidance for the selection of the appropriate model for various applications and discuss future trends and perspectives.},
  language  = {en}
}